Alex Hopkins
Research Subjects
Alex Hopkins has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Arul M. Chinnaiyan
Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
67 shared publications - Dan R. Robinson
Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI
67 shared publications - Veerabhadran Baladandayuthapani
Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA
67 shared publications - Yi-Mi Wu
University of Michigan 1 Ann Arbor, MI
67 shared publications - Aki Morikawa
University of Michigan 5 Department of Internal Medicine Ann Arbor, Michigan
48 shared publications - Athena Apfel
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan
48 shared publications
Latest Publications
- Open Access
- 9 June 2025
- Published by Springer Nature in Research Square
Sequencing analysis reveals evidence of immune activation in advanced HER2 negative breast cancer responders treated with entinostat + nivolumab + ipilimumab
We analyzed the pathways associated with therapeutic response in 19 patients (5 responders) enrolled in a Phase Ib trial (NCT02453620) diagnosed with advanced HER2-negative breast cancer and treated with the HDAC inhibitor entinostat, in combination with dual immune checkpoint inhibitors (ICIs), nivolumab and ipilimumab. The analysis included gene expression and T-cell receptor (TCR) repertoire data derived from bulk RNA-seq and neoantigen data from whole exome sequencing. A total of 37 tumor biopsies were taken from six different metastatic sites at three timepoints: before treatment (baseline), after a two-week entinostat run-in (C1D1), and after the dual ICIs were added (week 8). Paired differential gene expression (DE) analysis between different timepoints revealed changes in immune-related pathways, such as interferon gamma and inflammatory response, IL6/JAK/STAT3 and IL2/STAT5 signaling, and allograft rejection after week 8 of triplet treatment. The DE analysis of response at each timepoint also revealed significant changes at baseline in immune-related pathways, such as inflammatory and interferon alpha and gamma responses, suggesting that responders may have had a preexisting immune tumor microenvironment (TME) that primed them for triplet therapy. Further analysis of the TME revealed significantly higher expression of genes representative of subsets of CD8+ T and plasma cells after entinostat treatment, indicating potential mechanisms of TME sensitization by HDACi. Genes representative of M1-like macrophages, pDC, memory CD4+ T, B, NK, lymphatic endothelial, Th1 cells, and memory B cells were significantly altered in responders after triplet treatment. PAM50 molecular subtype analysis revealed that basal and luminal B subtypes correlate with response. TCR analysis demonstrated higher diversity, and exploratory analysis of strong binding neoantigens showed fewer strong neoantigen binders in responders at week 8. In summary, the sequencing analysis reveals important changes in the immune landscape of responders to the combined treatment of entinostat and ICIs and suggests that pretreatment with entinostat may sensitize the immune TME to promote response.
- 9 June 2025
- Published by Springer Nature in Research Square
Open AccessSequencing analysis reveals evidence of immune activation in advanced HER2 negative breast cancer responders treated with entinostat + nivolumab + ipilimumab
We analyzed the pathways associated with therapeutic response in 19 patients (5 responders) enrolled in a Phase Ib trial (NCT02453620) diagnosed with advanced HER2-negative breast cancer and treated with the HDAC inhibitor entinostat, in combination with dual immune checkpoint inhibitors (ICIs), nivolumab and ipilimumab. The analysis included gene expression and T-cell receptor (TCR) repertoire data derived from bulk RNA-seq and neoantigen data from whole exome sequencing. A total of 37 tumor biopsies were taken from six different metastatic sites at three timepoints: before treatment (baseline), after a two-week entinostat run-in (C1D1), and after the dual ICIs were added (week 8). Paired differential gene expression (DE) analysis between different timepoints revealed changes in immune-related pathways, such as interferon gamma and inflammatory response, IL6/JAK/STAT3 and IL2/STAT5 signaling, and allograft rejection after week 8 of triplet treatment. The DE analysis of response at each timepoint also revealed significant changes at baseline in immune-related pathways, such as inflammatory and interferon alpha and gamma responses, suggesting that responders may have had a preexisting immune tumor microenvironment (TME) that primed them for triplet therapy. Further analysis of the TME revealed significantly higher expression of genes representative of subsets of CD8+ T and plasma cells after entinostat treatment, indicating potential mechanisms of TME sensitization by HDACi. Genes representative of M1-like macrophages, pDC, memory CD4+ T, B, NK, lymphatic endothelial, Th1 cells, and memory B cells were significantly altered in responders after triplet treatment. PAM50 molecular subtype analysis revealed that basal and luminal B subtypes correlate with response. TCR analysis demonstrated higher diversity, and exploratory analysis of strong binding neoantigens showed fewer strong neoantigen binders in responders at week 8. In summary, the sequencing analysis reveals important changes in the immune landscape of responders to the combined treatment of entinostat and ICIs and suggests that pretreatment with entinostat may sensitize the immune TME to promote response.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Supplementary Table S3. Treatment exposure and reasons for discontinuation.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Supplementary Table S3. Treatment exposure and reasons for discontinuation.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Supplementary Figure S3. Unconfirmed PSA50 response.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Supplementary Figure S3. Unconfirmed PSA50 response.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Supplementary Table S4. External somatic CDK12 sequencing and NGS reports.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Supplementary Table S4. External somatic CDK12 sequencing and NGS reports.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Supplementary Figure S1. Trial schema design.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Supplementary Figure S1. Trial schema design.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Supplementary Table S2. Objective response rate (ORR) and radiographic progression-free survival (rPFS).
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Supplementary Table S2. Objective response rate (ORR) and radiographic progression-free survival (rPFS).
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Supplementary Figure S4. Time to PSA progression (TTP).
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Supplementary Figure S4. Time to PSA progression (TTP).
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Supplementary Figure S2. Cohort flow diagram for patients enrolled in cohorts A and C and those included in the analyses.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Supplementary Figure S2. Cohort flow diagram for patients enrolled in cohorts A and C and those included in the analyses.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Supplementary Figure S4. Time to PSA progression (TTP).
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Supplementary Figure S4. Time to PSA progression (TTP).
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Supplementary Table S1. Study representativeness.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Supplementary Table S1. Study representativeness.